Evidence map›Paper›PMID 42592745›Full record

ArticleHIV medicine2026

Material deprivation and its correlates in treatment-naïve migrants with HIV with rapid access to B/F/TAF at no cost: A sub-study of the ASAP cohort.

Moustafa Laymouna, Kim Engler, David Lessard, Melchior Belin, Serge Vicente, Dominic Chu, Sean Yaphe, Joseph Cox, Nadine Kronfli, Jean-Pierre Routy and 6 more

Abstract read
In one paragraph

Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Moustafa LaymounaDepartment of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0002-0673-6356
Kim EnglerCentre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0001-8364-7421
David LessardCentre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0002-1151-3763
Melchior BelinCentre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.
Serge VicenteCentre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0001-6478-4308
Dominic ChuDepartment of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0003-0645-1622
Sean YapheDepartment of Medicine, Chronic Viral Illness Service, Division of Infectious Diseases, McGill University Health Centre, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0001-8799-4703
Joseph CoxDepartment of Medicine, Chronic Viral Illness Service, Division of Infectious Diseases, McGill University Health Centre, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0002-7041-1556
Nadine KronfliCentre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0003-2724-0496
Jean-Pierre RoutyDepartment of Medicine, Chronic Viral Illness Service, Division of Infectious Diseases, McGill University Health Centre, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0001-9897-7589
Joel IshakCentre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.
Alexandra HamelDepartment of Medicine, Chronic Viral Illness Service, Division of Infectious Diseases, McGill University Health Centre, Montréal, Québec, Canada.
Marina KleinDepartment of Medicine, Chronic Viral Illness Service, Division of Infectious Diseases, McGill University Health Centre, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0002-3063-8430
Alexandra de PokomandyDepartment of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0001-6809-1357
Cecilia T CostiniukDepartment of Medicine, Chronic Viral Illness Service, Division of Infectious Diseases, McGill University Health Centre, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0002-4547-714X
Bertrand LebouchéDepartment of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0002-1273-9393

Funding

Gilead Sciences IN-US-380-4670
6 · The paper itself

Abstract

objectivesMaterial deprivation (MD), the inability to afford essentials, is linked with poorer HIV clinical outcomes. In Canada, migrants living with HIV are a growing group, yet little is known about their experience of MD, especially early in treatment. This study examined the prevalence, nature, sociodemographic and clinical correlates and longitudinal changes in MD among migrants living with HIV initiating antiretroviral therapy (ART).

methodsAnalyses used data from 56 ART-naïve migrants enrolled in the Antiretroviral Speed Access Program (ASAP), a cohort at the McGill University Health Centre, Montreal, Canada receiving access to rapid, no-cost and onsite bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). MD was assessed at Weeks 4 and 48 using the 17-item Canadian Material Deprivation Index (CMDI), with deprivation defined as checking ≥2 items. Statistical tests included Fisher's exact, Wilcoxon signed-rank, McNemar's exact and correlation coefficients.

resultsAt Week 4, 48 (85.7%) participants were materially deprived, most commonly reporting inability to cover an unexpected expense (87.5%), afford dental care (73.2%) or buy small gifts (73.2%). Week 4 MD was significantly associated with occupation (p = 0.020) and migration status (p = 0.016). No statistically significant associations were observed between MD and HIV clinical outcomes. Between Weeks 4 and 48, MD scores declined significantly (median: 7.5 to 4.0; p < 0.001), although 67.9% of participants remained deprived.

conclusionsAssociated with occupation and migrant status, MD was highly prevalent and persistent among migrants living with HIV, despite partial improvement over time, underscoring the need for structural supports. Short-term HIV clinical outcomes appeared unaffected, which may reflect access to rapid, no-cost and onsite ART delivery.

Indexed as

Anti-HIV AgentsHealth Services AccessibilityHIV InfectionsTransients and MigrantsAdultCanadaCohort StudiesFemaleHumansMaleMiddle AgedQuebecAnti-HIV AgentsHIVmaterial deprivationmigrantsrapid antiretroviral therapy initiationsocial determinants of health

Identifiers

PMID42592745
PMCPMC13631696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.